MedTrace Logo

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

NCT06160167 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4204

Last updated 2024-08-23

No results posted yet for this study

Summary

The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.

Conditions

Interventions

DRUG

IMiD treatment

Participants with MM treated with IMiDs

DRUG

No IMiD treatment

Participants with MM not treated with IMiDs

DRUG

Systemic therapy

Participants with MM treated with systemic therapy

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers-Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-08-01
Completion
2024-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06160167 on ClinicalTrials.gov